Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,860 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the transaction, the insider now directly owns 247,173 shares in the company, valued at approximately $8,952,606.06. This trade represents a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total value of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total value of $143,228.80.

Apogee Therapeutics Price Performance

APGE opened at $32.32 on Friday. The firm has a market capitalization of $1.46 billion, a PE ratio of -13.36 and a beta of 1.72. The business’s 50-day moving average is $37.21 and its two-hundred day moving average is $45.49. Apogee Therapeutics, Inc. has a 1 year low of $29.10 and a 1 year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, sell-side analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on APGE. Wedbush restated an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Citigroup initiated coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $95.00 target price on the stock. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $92.17.

Hedge Funds Weigh In On Apogee Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. boosted its position in shares of Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after purchasing an additional 438,036 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Apogee Therapeutics by 11.2% in the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after acquiring an additional 82,978 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Apogee Therapeutics by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock worth $16,472,000 after acquiring an additional 41,686 shares during the last quarter. Barclays PLC increased its holdings in shares of Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock valued at $21,443,000 after acquiring an additional 287,243 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Apogee Therapeutics in the 3rd quarter valued at approximately $300,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.